Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 17 new ...

And yet, data science is now poised to usher in a level and acceleration of progress that even life sciences have never ...

Dear ProMIS Shareholders, In my first year as the Chief Executive Officer of ProMIS, we made great strides advancing our mission-driven innovation focused on developing precision-targeted therapies ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: The Biopharmaceutical Contract ...

Mike Arthur, Shareholder, Audit, Nashville: Arthur returns to LBMC with more than 30 years of expertise in financial ...

The company also released additional data from its phase 2 clinical trial in addition to the LONGITUDE program design.

LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV)BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Dat ...

BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Data ...

Biocon shares rose 9% to ₹389, driven by positive developments including Japanese approval for its biosimilar Ustekinumab.

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

Anticipated growth for ‘Saudi Arabia Diagnostic Specialty Antibodies Market’ is significant from 2024 to 2032. The market showed steady growth in 2024 and is expected to continue rising due to ...